Barclays says reports of Eli Lilly (LLY) reportedly being in talks to acquire Scorpion Therapeutics has a positive read-through to Relay Therapeutics (RLAY) given their similar competitive ...

The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors.

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...